Li Y, Hellstrom K E, Newby S A, Chen L
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
J Exp Med. 1996 Feb 1;183(2):639-44. doi: 10.1084/jem.183.2.639.
Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficient immune response. We report here that two such tumors, the Ag104A sarcoma and the K1735-M2 melanoma, become immunogenic after transfection of the genes encoding murine B7-1 together with CD48, which is the natural ligand for CD2. Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells. A similar approach may be useful for developing therapy for other poorly immunogenic tumors, including those in humans.
对多种类型的小鼠肿瘤进行基因改造,使其表达T细胞共刺激分子CD28的天然配体B7-1或B7-2分子,可增强其免疫原性。然而,即使在用B7-1和/或B7-2基因转染后,免疫原性较差的肿瘤仍无法引发有效的免疫反应。我们在此报告,两种这样的肿瘤,即Ag104A肉瘤和K1735-M2黑色素瘤,在转染编码小鼠B7-1的基因以及CD48(CD2的天然配体)后变得具有免疫原性。肿瘤特异性CD8+细胞毒性T淋巴细胞很容易产生,并且对野生型Ag104A肉瘤细胞诱导的转移的过继免疫治疗有效。类似的方法可能有助于开发针对其他免疫原性较差的肿瘤(包括人类肿瘤)的治疗方法。